Go Pro
→ What Elon told his top shareholders in Texas (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
$1.55
-2.5%		$1.83
$1.07
▼
$6.18
$95.91M1.211.06 million shs1.17 million shs
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
$2.36
+1.3%		$2.19
$1.65
▼
$3.07
$25.01M0.2524,615 shs38,139 shs
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$2.67
-3.6%		$3.06
$1.81
▼
$4.53
$92.02M1.21700,083 shs579,832 shs
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$5.08
-5.2%		$5.79
$3.28
▼
$9.82
$92.08M1.4929,161 shs126,277 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
-2.52%+0.65%-27.23%-10.40%-70.31%
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
+1.29%+5.83%+8.26%-5.60%-2.88%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-3.61%-14.70%-11.00%+11.72%+42.02%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-5.22%-2.68%-23.26%-36.42%-16.86%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
$1.55
-2.5%		$1.83
$1.07
▼
$6.18
$95.91M1.211.06 million shs1.17 million shs
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
$2.36
+1.3%		$2.19
$1.65
▼
$3.07
$25.01M0.2524,615 shs38,139 shs
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$2.67
-3.6%		$3.06
$1.81
▼
$4.53
$92.02M1.21700,083 shs579,832 shs
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$5.08
-5.2%		$5.79
$3.28
▼
$9.82
$92.08M1.4929,161 shs126,277 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
-2.52%+0.65%-27.23%-10.40%-70.31%
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
+1.29%+5.83%+8.26%-5.60%-2.88%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-3.61%-14.70%-11.00%+11.72%+42.02%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-5.22%-2.68%-23.26%-36.42%-16.86%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
2.00
Hold$5.50254.84% Upside
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
2.00
Hold$10.75355.51% Upside
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
2.25
Hold$17.00536.70% Upside
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
2.25
Hold$14.50185.43% Upside

Current Analyst Ratings Breakdown

Latest AYTU, ALDX, FBIO, and VRCA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2026
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/15/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/8/2026
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
7/6/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/11/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$14.00 ➝ $14.50
5/26/2026
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
5/20/2026
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
5/18/2026
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
5/11/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
5/11/2026
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
N/AN/AN/AN/A$0.74 per shareN/A
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
$66.38M0.38$0.38 per share6.21$2.11 per share1.12
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$66.16M1.34N/AN/A$2.00 per share1.34
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$35.58M2.45N/AN/A$1.55 per share3.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
-$33.85M-$0.46N/AN/AN/AN/A-57.34%-36.33%N/A
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
-$13.56M-$4.58N/A9.44N/A-60.17%-69.93%-13.25%9/29/2026 (Estimated)
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$6.82M$3.170.84N/AN/A193.12%109.66%45.56%8/13/2026 (Estimated)
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$17.89M-$1.03N/AN/AN/A-102.84%-360.69%-67.57%N/A

Latest AYTU, ALDX, FBIO, and VRCA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$0.20N/AN/AN/A$18.30 millionN/A
8/6/2026Q2 2026
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
-$0.0875-$0.09-$0.0025-$0.09$31.33 millionN/A
5/14/2026Q1 2026
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$0.22$2.82+$3.04$2.82$16.34 million$16.04 million
5/13/2026Q3 2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
-$0.4433-$0.53-$0.0867-$0.53$12.05 million$12.41 million
5/12/2026Q1 2026
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.59-$0.41+$0.18-$0.45$4.51 million$5.02 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
N/AN/AN/AN/AN/A
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
N/A
2.72
2.72
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
0.27
1.12
1.00
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
0.18
2.86
2.77
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
0.03
2.10
1.98

Institutional Ownership

CompanyInstitutional Ownership
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
59.71%
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
33.49%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
42.45%

Insider Ownership

CompanyInsider Ownership
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
11.80%
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
4.90%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
28.50%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
52.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
1060.32 million53.20 millionOptionable
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
16010.73 million10.21 millionNot Optionable
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
17033.22 million23.75 millionOptionable
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
4017.18 million8.09 millionNo Data

Recent News About These Companies

Verrica Pharmaceuticals Q2 Earnings Call Highlights
August 7 at 3:03 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/verrica-pharmaceuticals-q2-earnings-call-highlights-2026-08-07/
Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript
August 7 at 8:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4932965-verrica-pharmaceuticals-inc-vrca-q2-2026-earnings-call-transcript
Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results
August 6 at 12:25 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/verrica-pharmaceuticals-nasdaqvrca-releases-earnings-results-2026-08-06/
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates
August 6 at 8:12 PM  |  zacks.comhttps://www.zacks.com/stock/news/2970483/verrica-pharmaceuticals-inc-vrca-reports-q2-loss-beats-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2970483
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 6 at 7:35 PM  |  manilatimes.netM
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
August 6 at 7:35 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/verrica-pharmaceuticals-closes-credit-facility-200100868.html
Verrica Pharmaceuticals (VRCA) Projected to Release Quarterly Earnings on Thursday
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/verrica-pharmaceuticals-vrca-projected-to-release-quarterly-earnings-on-thursday-2026-08-02/
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Average Rating of "Hold" from Analysts
July 31, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30931981
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
July 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/30/3335994/0/en/verrica-pharmaceuticals-to-report-second-quarter-2026-financial-results-and-provide-a-corporate-update-on-august-6-2026.html
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Recommendation of "Hold" by Brokerages
July 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/verrica-pharmaceuticals-inc-nasdaqvrca-given-consensus-recommendation-of-hold-by-brokerages-2026-07-26/
Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to Sell at Wall Street Zen
July 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/verrica-pharmaceuticals-nasdaqvrca-cut-to-sell-at-wall-street-zen-2026-07-25/
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum ...
July 21, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-marketing-and-supply-agreement-to-commercialize-ycanth-for-the-treatment-of-molluscum-contagiosum-in-israel-1036345739
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330404/0/en/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-marketing-and-supply-agreement-to-commercialize-ycanth-for-the-treatment-of-molluscum-contagiosum-in-is.html
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment ...
June 23, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/verrica-pharmaceuticals-announces-first-u-s-patient-dosed-in-the-second-pivotal-clinical-trial-cove-3-of-its-phase-3-program-evaluating-ycanth-vp-102-for-the-treatment-of-common-warts-1036264896
Verrica Pharmaceuticals Announces First U.S. and Japanese Patients Dosed in Phase 3 COVE-3 Trial of YCANTH for Common Warts
June 22, 2026  |  quiverquant.comQ
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315264/0/en/verrica-pharmaceuticals-announces-first-u-s-patient-dosed-in-the-second-pivotal-clinical-trial-cove-3-of-its-phase-3-program-evaluating-ycanth-vp-102-for-the-treatment-of-common-wa.html
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/28/3302812/0/en/verrica-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference.html
Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
May 13, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/verrica-pharmaceuticals-inc-vrca-q1-050137147.html
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/13/3293921/0/en/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq.html
Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript
May 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4903533-verrica-pharmaceuticals-inc-vrca-q1-2026-earnings-call-transcript
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
May 12, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2920083/verrica-pharmaceuticals-inc-vrca-reports-q1-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2920083

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aldeyra Therapeutics stock logo

Aldeyra Therapeutics NASDAQ:ALDX

$1.55 -0.04 (-2.52%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$1.58 +0.02 (+1.61%)
As of 08/7/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Aytu BioPharma stock logo

Aytu BioPharma NASDAQ:AYTU

$2.36 +0.03 (+1.29%)
Closing price 08/7/2026 03:59 PM Eastern
Extended Trading
$2.35 -0.01 (-0.42%)
As of 08/7/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Fortress Biotech stock logo

Fortress Biotech NASDAQ:FBIO

$2.67 -0.10 (-3.61%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$2.68 +0.01 (+0.37%)
As of 08/7/2026 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Verrica Pharmaceuticals stock logo

Verrica Pharmaceuticals NASDAQ:VRCA

$5.08 -0.28 (-5.22%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$5.14 +0.06 (+1.28%)
As of 08/7/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas